We would like to update you on the change of the CEEGOG residence. The proposal for the new place of residence was approved by all participants at the CEEGOG meeting in December 2016. Starting June, 2017, the Association resides in the city of Prague, Na Folimance 2155/15, Praha 2 – Vinohrady.
Finally, there is an upcoming meeting with the industry in October 2017, where Ph1/Ph2 representatives will present their trial proposals. In relation to that, prof. Vergote spoke about the existing ENGOT rules on the cooperation with the industry
On March 3 - 4, 2017, a meeting of representatives of the twenty national trial groups was held in Spanish Valencia. CEEGOG was represented by its Chairman Prof. David Cibula and the administrative manager Mrs. Ivana Nohová.
Have previously been diagnosed and treated for ovarian cancer, peritoneal cancer, and/or fallopian tube cancer and their disease has come back.
Have an inherited BRCA mutation. In case of an unknown BRCA status, patients are eligible to undergo BRCA testing even if they have not yet had recurrence or progression of disease >6 months (>/=183 days) after completion of their last platinum therapy. Note: The BRCA test is covered by the sponsor.
We would like to express our thanks for your participation in the CEEGOG meeting held in Prague on December 9, 2016. It is our pleasure to invite the 9 new centers for cooperation. Currently CEEGOG is composed of 39 centres from 8 countries – the Czech Republic, Slovakia, Poland, Slovenia, Ukraine, Hungary, Belarus, Georgia.
We would like to invite CEEGOG members and friends to the CEEGOG meeting, which is going to be held at the General University Hospital in Prague on Friday, December 9, 2016, from 9:30 am to 16:00 pm. Both CEEGOG members and CEEGOG friends are cordially invited to attend the meeting.
Page 5 of 7